TY  - JOUR
AU  - Heneka, Michael
AU  - Carson, Monica J
AU  - El Khoury, Joseph
AU  - Landreth, Gary E
AU  - Brosseron, Frederic
AU  - Feinstein, Douglas L
AU  - Jacobs, Andreas H
AU  - Wyss-Coray, Tony
AU  - Vitorica, Javier
AU  - Ransohoff, Richard M
AU  - Herrup, Karl
AU  - Frautschy, Sally A
AU  - Finsen, Bente
AU  - Brown, Guy C
AU  - Verkhratsky, Alexei
AU  - Yamanaka, Koji
AU  - Koistinaho, Jari
AU  - Latz, Eicke
AU  - Halle, Annett
AU  - Petzold, Gabor C
AU  - Town, Terrence
AU  - Morgan, Dave
AU  - Shinohara, Mari L
AU  - Perry, V Hugh
AU  - Holmes, Clive
AU  - Bazan, Nicolas G
AU  - Brooks, David J
AU  - Hunot, Stéphane
AU  - Joseph, Bertrand
AU  - Deigendesch, Nikolaus
AU  - Garaschuk, Olga
AU  - Boddeke, Erik
AU  - Dinarello, Charles A
AU  - Breitner, John C
AU  - Cole, Greg M
AU  - Golenbock, Douglas T
AU  - Kummer, Markus P
TI  - Neuroinflammation in Alzheimer's disease.
JO  - The lancet  / Neurology
VL  - 14
IS  - 4
SN  - 1474-4422
CY  - London
PB  - Lancet Publ. Group
M1  - DZNE-2020-04173
SP  - 388-405
PY  - 2015
AB  - Increasing evidence suggests that Alzheimer's disease pathogenesis is not restricted to the neuronal compartment, but includes strong interactions with immunological mechanisms in the brain. Misfolded and aggregated proteins bind to pattern recognition receptors on microglia and astroglia, and trigger an innate immune response characterised by release of inflammatory mediators, which contribute to disease progression and severity. Genome-wide analysis suggests that several genes that increase the risk for sporadic Alzheimer's disease encode factors that regulate glial clearance of misfolded proteins and the inflammatory reaction. External factors, including systemic inflammation and obesity, are likely to interfere with immunological processes of the brain and further promote disease progression. Modulation of risk factors and targeting of these immune mechanisms could lead to future therapeutic or preventive strategies for Alzheimer's disease.
KW  - Alzheimer Disease: genetics
KW  - Alzheimer Disease: immunology
KW  - Alzheimer Disease: metabolism
KW  - Alzheimer Disease: pathology
KW  - Alzheimer Disease: prevention & control
KW  - Animals
KW  - Anti-Inflammatory Agents, Non-Steroidal: therapeutic use
KW  - Astrocytes: immunology
KW  - Astrocytes: pathology
KW  - Biomarkers: blood
KW  - Biomarkers: cerebrospinal fluid
KW  - Brain Injuries: complications
KW  - Brain Injuries: metabolism
KW  - Clinical Trials as Topic
KW  - Disease Models, Animal
KW  - Disease Progression
KW  - Humans
KW  - Immunity, Innate
KW  - Immunization
KW  - Inflammation: diagnosis
KW  - Inflammation: immunology
KW  - Inflammation: metabolism
KW  - Inflammation Mediators: immunology
KW  - Inflammation Mediators: metabolism
KW  - Locus Coeruleus: pathology
KW  - Microglia: immunology
KW  - Microglia: pathology
KW  - Nootropic Agents: administration & dosage
KW  - Obesity: complications
KW  - Obesity: metabolism
KW  - Phagocytosis
KW  - Protein Folding
KW  - Risk Factors
KW  - Severity of Illness Index
KW  - Anti-Inflammatory Agents, Non-Steroidal (NLM Chemicals)
KW  - Biomarkers (NLM Chemicals)
KW  - Inflammation Mediators (NLM Chemicals)
KW  - Nootropic Agents (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:25792098
C2  - pmc:PMC5909703
DO  - DOI:10.1016/S1474-4422(15)70016-5
UR  - https://pub.dzne.de/record/137851
ER  -